GDF15 is a putative biomarker for distinguishing pulmonary veno-occlusive disease and pulmonary arterial hypertension.
Saved in:
| Title: | GDF15 is a putative biomarker for distinguishing pulmonary veno-occlusive disease and pulmonary arterial hypertension. |
|---|---|
| Authors: | Prabhakar A; Cardiovascular Research Institute, UCSF, San Francisco, California, USA., De Bie EM; Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, United Kingdom.; Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom., DesJardin JT; Pulmonary Vascular Disease, PAH Center of Comprehensive Care, Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA., Ghatpande P; Cardiovascular Research Institute, UCSF, San Francisco, California, USA., Gräf S; Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, United Kingdom., Howard LS; Imperial College London Faculty of Medicine, National Heart & Lung Institute, London, United Kingdom.; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Wort SJ; Imperial College London Faculty of Medicine, National Heart & Lung Institute, London, United Kingdom.; Royal Brompton Hospital, Adult Centre for Pulmonary Hypertension, London, United Kingdom., Church C; Golden Jubilee National University Hospital and University of Glasgow, Glasgow, United Kingdom., Kiely DG; Sheffield Pulmonary Vascular Disease Unit and NIHR Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, UK and Clinical Medicine, University of Sheffield, Sheffield, United Kingdom., Sumpena E; Pulmonary Vascular Disease, PAH Center of Comprehensive Care, Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA., Aung T; Pulmonary Vascular Disease, PAH Center of Comprehensive Care, Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA., Carter S; Pulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA., Kukreja J; Department of Cardiothoracic Surgery, UCSF, San Francisco, California, USA., Hays S; Pulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA., Greenland JR; Pulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA.; San Francisco VA Health Care System, San Francisco, California, USA., Singer JP; Pulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA., Wax M; Pulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA., Wolters PJ; Pulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA., Simon MA; Pulmonary Vascular Disease, PAH Center of Comprehensive Care, Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA., Toshner M; Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, United Kingdom.; Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom., Lagna G; Cardiovascular Research Institute, UCSF, San Francisco, California, USA., Hata A; Cardiovascular Research Institute, UCSF, San Francisco, California, USA.; Department of Biochemistry and Biophysics, UCSF, San Francisco, California, USA. |
| Corporate Authors: | UK Pulmonary Arterial Hypertension Cohort Study Consortium |
| Source: | The Journal of clinical investigation [J Clin Invest] 2025 Nov 20; Vol. 136 (2). Date of Electronic Publication: 2025 Nov 20 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: eCollection Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
